vs

Side-by-side financial comparison of OppFi Inc. (OPFI) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $85.6M, roughly 1.8× OppFi Inc.). OppFi Inc. runs the higher net margin — 19.7% vs -5.5%, a 25.2% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 5.9%). OppFi Inc. produced more free cash flow last quarter ($382.2M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 16.3%).

OppFi Inc. is a US-headquartered financial technology firm that provides responsible, accessible financial solutions including installment loans, credit-building tools and related support services to consumers underserved by traditional banking institutions, prioritizing fair terms to help users boost their long-term financial wellness.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

OPFI vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.8× larger
TARS
$151.7M
$85.6M
OPFI
Growing faster (revenue YoY)
TARS
TARS
+122.5% gap
TARS
128.4%
5.9%
OPFI
Higher net margin
OPFI
OPFI
25.2% more per $
OPFI
19.7%
-5.5%
TARS
More free cash flow
OPFI
OPFI
$369.2M more FCF
OPFI
$382.2M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
16.3%
OPFI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OPFI
OPFI
TARS
TARS
Revenue
$85.6M
$151.7M
Net Profit
$16.8M
$-8.4M
Gross Margin
Operating Margin
36.1%
-5.3%
Net Margin
19.7%
-5.5%
Revenue YoY
5.9%
128.4%
Net Profit YoY
400.3%
63.8%
EPS (diluted)
$1.48
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OPFI
OPFI
TARS
TARS
Q4 25
$85.6M
$151.7M
Q3 25
$104.6M
$118.7M
Q2 25
$100.2M
$102.7M
Q1 25
$90.8M
$78.3M
Q4 24
$80.8M
$66.4M
Q3 24
$91.2M
$48.1M
Q2 24
$86.3M
$40.8M
Q1 24
$63.2M
$27.6M
Net Profit
OPFI
OPFI
TARS
TARS
Q4 25
$16.8M
$-8.4M
Q3 25
$41.6M
$-12.6M
Q2 25
$-20.8M
$-20.3M
Q1 25
$-11.4M
$-25.1M
Q4 24
$-5.6M
$-23.1M
Q3 24
$4.3M
$-23.4M
Q2 24
$3.1M
$-33.3M
Q1 24
$5.5M
$-35.7M
Operating Margin
OPFI
OPFI
TARS
TARS
Q4 25
36.1%
-5.3%
Q3 25
46.3%
-12.2%
Q2 25
44.7%
-21.6%
Q1 25
46.8%
-33.5%
Q4 24
30.5%
-36.8%
Q3 24
38.5%
-52.3%
Q2 24
34.2%
-81.6%
Q1 24
8.4%
-136.5%
Net Margin
OPFI
OPFI
TARS
TARS
Q4 25
19.7%
-5.5%
Q3 25
39.8%
-10.6%
Q2 25
-20.7%
-19.8%
Q1 25
-12.5%
-32.1%
Q4 24
-6.9%
-34.8%
Q3 24
4.7%
-48.7%
Q2 24
3.6%
-81.6%
Q1 24
8.8%
-129.4%
EPS (diluted)
OPFI
OPFI
TARS
TARS
Q4 25
$1.48
$-0.17
Q3 25
$0.77
$-0.30
Q2 25
$-0.78
$-0.48
Q1 25
$-0.48
$-0.64
Q4 24
$-0.11
$-0.57
Q3 24
$0.21
$-0.61
Q2 24
$0.16
$-0.88
Q1 24
$0.10
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OPFI
OPFI
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$49.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$58.5M
$343.4M
Total Assets
$754.1M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OPFI
OPFI
TARS
TARS
Q4 25
$49.5M
$417.3M
Q3 25
$45.5M
$401.8M
Q2 25
$45.2M
$381.1M
Q1 25
$58.0M
$407.9M
Q4 24
$61.3M
$291.4M
Q3 24
$44.8M
$317.0M
Q2 24
$46.6M
$323.6M
Q1 24
$47.2M
$298.5M
Total Debt
OPFI
OPFI
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
OPFI
OPFI
TARS
TARS
Q4 25
$58.5M
$343.4M
Q3 25
$49.4M
$335.1M
Q2 25
$13.4M
$332.6M
Q1 25
$22.6M
$342.5M
Q4 24
$32.8M
$224.5M
Q3 24
$34.9M
$237.5M
Q2 24
$18.6M
$252.2M
Q1 24
$18.2M
$275.2M
Total Assets
OPFI
OPFI
TARS
TARS
Q4 25
$754.1M
$562.2M
Q3 25
$720.6M
$534.6M
Q2 25
$673.4M
$495.0M
Q1 25
$640.1M
$500.8M
Q4 24
$641.2M
$377.0M
Q3 24
$619.3M
$376.3M
Q2 24
$573.1M
$376.8M
Q1 24
$563.2M
$349.3M
Debt / Equity
OPFI
OPFI
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OPFI
OPFI
TARS
TARS
Operating Cash FlowLast quarter
$401.3M
$19.3M
Free Cash FlowOCF − Capex
$382.2M
$13.0M
FCF MarginFCF / Revenue
446.6%
8.6%
Capex IntensityCapex / Revenue
22.3%
4.2%
Cash ConversionOCF / Net Profit
23.82×
TTM Free Cash FlowTrailing 4 quarters
$652.5M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OPFI
OPFI
TARS
TARS
Q4 25
$401.3M
$19.3M
Q3 25
$105.1M
$18.3M
Q2 25
$95.6M
$-29.4M
Q1 25
$83.7M
$-20.7M
Q4 24
$323.8M
$-22.2M
Q3 24
$77.6M
$-8.7M
Q2 24
$77.3M
$-14.4M
Q1 24
$74.4M
$-37.8M
Free Cash Flow
OPFI
OPFI
TARS
TARS
Q4 25
$382.2M
$13.0M
Q3 25
$99.9M
$16.3M
Q2 25
$91.0M
$-30.4M
Q1 25
$79.3M
$-21.2M
Q4 24
$310.8M
$-22.3M
Q3 24
$73.7M
$-8.9M
Q2 24
$74.7M
$-15.4M
Q1 24
$72.3M
$-38.0M
FCF Margin
OPFI
OPFI
TARS
TARS
Q4 25
446.6%
8.6%
Q3 25
95.6%
13.8%
Q2 25
90.8%
-29.6%
Q1 25
87.4%
-27.1%
Q4 24
384.6%
-33.5%
Q3 24
80.8%
-18.6%
Q2 24
86.6%
-37.8%
Q1 24
114.4%
-137.5%
Capex Intensity
OPFI
OPFI
TARS
TARS
Q4 25
22.3%
4.2%
Q3 25
5.0%
1.6%
Q2 25
4.6%
1.0%
Q1 25
4.8%
0.8%
Q4 24
16.1%
0.1%
Q3 24
4.3%
0.6%
Q2 24
3.0%
2.5%
Q1 24
3.4%
0.6%
Cash Conversion
OPFI
OPFI
TARS
TARS
Q4 25
23.82×
Q3 25
2.52×
Q2 25
Q1 25
Q4 24
Q3 24
18.19×
Q2 24
25.21×
Q1 24
13.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons